All funding for this site is provided directly by ESMO. eCollection 2022 Apr. All of these reported symptoms and signs occurred within an hour of initiating carboplatin administration. 107, 163165. All funding for this site is provided directly by ESMO. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. 15, 780784. 2008;14(27):2892-901. doi: 10.2174/138161208786369803. 24, 46994707. Bayer to Highlight New Research at ESMO 2017 Congress Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcRI. Cumulative incidence of carboplatin-related hypersensitivity reactions according to the carboplatin administration cycle number (A) and carboplatin dose (B). Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase1 Study of Intravenous Fosnetupitant. Management of infusion reactions to systemic anticancer therapy: ESMO Gynecol. Recently, more and more patients with ovarian cancer have been receiving genetic counseling and testing, including BRCA1/2 and the other heterologous recombinant deficient (HRD) genes, because of the development of PAPP inhibitors. Anticancer. This site uses cookies. Clinical Practice Guidelines on Supportive Care - ESMO (2009) reported the successful re-treatment of the majority of patients with previous carboplatin-related hypersensitivity reactions. Analysis and interpretation of data: Y-HT, Y-JT, H-CH, Y-YC, and W-FC. In the present study, 61 patients with carboplatin-related hypersensitivity were rechallenged with carboplatin. (33)]. (2016). doi: 10.2217/imt.14.71, Chiang, Y. C., Chen, C. A., Chiang, C. J., Hsu, T. H., Lin, M. C., You, S. L., et al. This site needs JavaScript to work properly. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. doi: 10.1111/IGC.0b013e3181a418ff, Greene, D. P., Ferriss, J. S., and Jazaeri, A. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. doi: 10.1016/S0140-6736(03)13718-X, Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et al. Lancet 361, 20992106. The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B). Prior investigations reported that a history of drug allergies correlates with the incidence of carboplatin-related hypersensitivity reactions (Libra et al., 2003; Sliesoraitis and Chikhale, 2005). The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Characteristics of the 735 women receiving carboplatin-based chemotherapy. PH IV/PH FDC SC for HER2-positive BC were well tolerated, with few grade 3 anaphylaxis/hypersensitivity events reported with PH IV and no grade 3 related events with PH FDC SC. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Among the 651 women (88.6%) diagnosed with ovarian cancer, 474 (64.5%) had stage IIIIV disease. Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment. HHS Vulnerability Disclosure, Help S.M. Monitor. A Comprehensive Methodology to Systematically Identify Drug - Springer ESMO 2019 Congress | OncologyPRO Table 3. ESMO is a Swiss-registered not-for-profit organisation. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. Res. Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. Int. Chemother. Tumori 89, 311313. 2022 Jun 16;3:868300. doi: 10.3389/falgy.2022.868300. Carboplatin and pegylated liposomal doxorubicin (Pujade-Lauraine et al., 2010) or gemcitabine (Pfisterer et al., 2006) led to superior progression-free survival of patients with platinum-sensitive recurrent ovarian cancer compared to paclitaxel and carboplatin. Carboplatin-related hypersensitivity reactions sometimes result in premature discontinuation of treatment (Schwartz et al., 2007). Carriers of BRCA genes develop drug allergy after fewer exposures and can present with severe reactions, including anaphylaxis. de Las Vecillas Snchez L, Alenazy LA, Garcia-Neuer M, Castells MC. Epub 2011 Jan 26. It didn't disappoint. Check the latest publications and updates here to make sure you dont miss anything. The research protocol was reviewed and approved by the institutional review board of the hospital. Statistical analyses were performed using the Statistical Package of Social Studies (SPSS) version 17.0 (SPSS, Inc., Chicago, IL) and SAS software version 9.4 (SAS Inc, NC, USA) for Windows. Such reactions could potentially be reduced or prevented by slowing the infusion rate and using a desensitization protocol involving anti-allergy medications. Here's a summary of the new ESMO guidelines in 5 key areas: . doi: 10.1093/annonc/mdt333. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). In addition, the development of a new generation of platinum cytotoxic drugs to avoid hypersensitivity reactions is warranted. J Exp Clin Cancer Res (2011) 30:93.10.1186/1756-9966-30-93 official website and that any information you provide is encrypted TABLE 3 Table 3. Received: 23 July 2017; Accepted: 23 October 2017; Published: 06 November 2017. We analyzed the relationships among the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions in this patient population. 105, 14721479. Monitor. The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. Assess for pustules or blisters or erosions in addition to areas of "dusky erythema" which may feel painful to palpation. Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan van de Loosdrecht, Arjan A. doi: 10.1200/JCO.1999.17.4.1141, Moon, D. H., Lee, J. M., Noonan, A. M., Annunziata, C. M., Minasian, L., Houston, N., et al. 2022 Dec;11(12):1405-1418. doi: 10.1002/cpdd.1183. ESMO 2017 Congress | Madrid, Spain | Oncology Conferences Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app. Int. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., et al. Supporting your clinical decisions with ESMOs regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession. View the photographic highlights from ESMO 2017 here! Hypersensitivity & Infusion Reaction Management Author: Updated 2.21.19 Subject: SCC Pharmacy sharing sensitive information, make sure youre on a federal 2017;40(3):120-127. doi: 10.1159/000458443. One-fifth of these patients never attempt carboplatin reinfusion, even after only mild hypersensitivity reactions (Gadducci et al., 2008). Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Zhi. All funding for this site is provided directly by ESMO. (2009). Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. Close monitoring is warranted for patients with a history of drug or food allergy, malignant ascites, or cumulative carboplatin dose >4,000 mg. Strategies for preventing carboplatin-related hypersensitivity include reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications. (2010) described the use of cisplatin as an alternative to carboplatin. doi: 10.1111/IGC.0b013e3181a1bf2e, Ledermann, J. Study conception and design: Y-HT and W-FC. Lacouture, V. Sibaud, P.A. Management of toxicities from immunotherapy: ESMO Clinical Practice An official website of the United States government. J. Gynecol. However, basophil activation has been observed in patients with a history of severe carboplatin hypersensitivity reaction (Iwamoto et al., 2014). Table 6. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? 66, 730. Reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications are especially important for patients at high risk of carboplatin hypersensitivity to detect the hypersensitivity early and avoid severe hypersensitivity without compromising the efficacy of the antineoplastic regimen. (2005). Virtually all chemotherapeutic agents have the potential to initiate infusion reactions, defined in this review as unexpected reactions that cannot be explained by the known toxicity profile of the drug. Markman, M. (2007). J Investig Allergol Clin Immunol. government site. Ann. Blood. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. Death from anaphylaxis to cisplatin: a case report. Would you like email updates of new search results? ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Furthermore, Moon et al. Gynecol. J. Clin. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Immunotherapy 6, 905912. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. (2009). 2018 Oct 1;29(Suppl 4):iv260. doi: 10.1093/annonc/mdy158. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Whether desensitization modulates drug allergic and anaphylactic responses facilitating tolerance is currently being investigated. Hypersensitivity reactions are generally unexpected, regulated by the immune system, and allergic in nature. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. doi: 10.1007/s10147-014-0731-1. Carboplatin rechallenge after hypersensitivity reactions in pediatric patients with low-grade glioma. doi: 10.1200/JCO.2003.02.153, Parmar, M. K., Ledermann, J. Prevention and Management of Dermatological Toxicities Related - ESMO sharing sensitive information, make sure youre on a federal Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. Infusion reactions to systemic chemotherapy - UpToDate Open. eCollection 2022. Patients with prior drug or food allergies should be closely monitored during carboplatin administration. These differences were likely related to the fact that patients with advanced disease, serous carcinoma, and ascetic malignant cells required significantly more carboplatin treatment cycles and higher carboplatin doses. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. This Webinar series brings together all the relevant stakeholders who are developing each guideline, as well as those who are consulting and implementing the guideline. ESMO Virtual Congress 2020 | OncologyPRO Severe carboplatin-related hypersensitivity reactions are uncommon. Acquisition of data: Y-HT, S-PL, Y-CC, Y-LC. doi: 10.1016/j.ygyno.2006.04.002, Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et al. Cancer. Evaluating whether any factors can predict carboplatin hypersensitivity, we identified a high correlation with the carboplatin cycle and cumulative dose (Pearson correlation coefficient 0.9318). Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions. government site. Front. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, etc. -. (2012) demonstrated that carboplatin treatment can be continued successfully in patients whose hypersensitivity reactions are managed in a timely fashion. Federal government websites often end in .gov or .mil. Oncol. Oncol. No use, distribution or reproduction is permitted which does not comply with these terms. Department of Pharmacological and Biomolecular Sciences, Faculty of Pharmacy, University of Milan, Italy, Ospedale Oncologico Armando Businco, Italy, University of Arkansas for Medical Sciences, United States. Although infusion reactions can be allergic or non-immune-mediated, the clinical manifestations are the same and require prompt assessment and appropriate intervention. 2022 Mar 30;9(4):26. doi: 10.3390/medicines9040026. Reactions to taxenes including paclitaxel and docetaxel present with pain as a neuromuscular symptoms in up to 4% of the patients. With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. The ESMO Congress is the most influential annual meeting for oncology professionals in Europe. doi: 10.1200/JOP.18.00761. 'Allergy' is a hypersensitivity reaction (HSR) initiated by specic immunolo- gical mechanisms. Information for media including press accreditation. Though the characteristics of carboplatin-related hypersensitivity reactions are widely reported, limited data are available regarding such reactions in different types of patients. For more detailed information on the cookies we use, please check our Privacy Policy. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. Successful carboplatin desensitization in patients with proven carboplatin allergy. A total of 735 eligible women who underwent treatment for ovarian, fallopian tube, or primary peritoneal cancer were recruited this the study; 75 (10.2%) experienced a total of 215 carboplatin-related hypersensitivity reaction events. For more detailed information on the cookies we use, please check our Privacy Policy. 84, 378382. Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Type II hypersensitivity is an IgG or IgM antibody-dependent cytotoxicity in which an antigen attached to cell membranes of red blood cells or platelets binds to an antibody, leading to cell or tissue damage such as haemolytic anaemia or thrombocytopenia. These scores have been defined by the guideline authors and validated by the ESMO Translational Research and Precision Medicine Working Group.17 g Selpercatinib is EMA approved for treating adults with advanced or metastatic RET fusion-positive TC who had already received lenvatinib or sorafenib. Desensitization is a high risk procedure in which a drug is administrated to a patient who has already presented an allergic reaction, almost always severe. Table 4. Would you like email updates of new search results? Epub 2022 Nov 29. We performed tests on occupational exposure (from 10 different health care surfaces) from three types of chemotherapy (Cyclophosphamide, Gemcitabine and Fluorouracil) from three different hospitals in Sweden. ESMO is a Swiss-registered not-for-profit organisation. Ann Oncol. Necessary cookies enable core functionality. A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) across all pivotal trials cited in the current EMA P IV/PH FDC SC SmPCs. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. These new ESMO Clinical Practice Guidelines provide tools to evaluate the risk of infusion reactions, to recognise the early signs and symptoms and include recommendations on how to document and manage them. Among these 75 women, 16 (21.3%) experienced severe hypersensitivity reactions (grades 3 and 4). Management of infusion reactions to systemic anticancer therapy: ESMO The annual ESMO Congress is the most prestigious and influential oncology platform in Europe and is the ideal place to learn about the latest science, network with colleagues and keep pace with today's rapid developments in cancer research. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. The drug or food allergy in 735 patients receiving carboplatin-based chemotherapy. doi: 10.1038/bjc.2013.389, Navo, M., Kunthur, A., Badell, M. L., Coffer, L. W. The ESMOClinical Practice Guidelines(CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings ofevidence-based medicine. (2010). Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. Furthermore, patients with carboplatin hypersensitivity had a higher incidence of previous allergic history to other cytotoxic drugs, including gemcitabine, paclitaxel, and doxorubicin, compared to those without (12/75 vs. 30/660, P < 0.001, chi-squared test; Table 7). Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. The tests were analyzed at an accredited lab according to protocol. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. 144, 7782. Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes. There is a need to further characterise risk of anaphylaxis/hypersensitivity with PH IV/PH FDC SC to support safe administration outside of clinics. Evaluation of the incidence of carboplatin hypersensitivity in cancer patients. and transmitted securely. *Correspondence: Wen-Fang Cheng, wenfangcheng@yahoo.com, Creative Commons Attribution License (CC BY). Assess for lymphadenopathy, facial or distal extremity swelling (may be signs of drug-induced hypersensitivity syndrome/DRESS). Algorithm for the evaluation of drug hypersensitivity reactions and the role of desensitization for the re-introduction of the first-line medications, when no alternative is available or the alternative does not provide the same benefits or life expectancy as the first line. Therefore, disease severity, histological type, malignant ascites, past drug allergies, and cumulative carboplatin dose are risk factors for carboplatin-related hypersensitivity reactions. doi: 10.1159/000055363, Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., et al. Summary format including algorithms, figures andtables for your presentations. These risk factors can help identify patients at greater risk of developing hypersensitivity. Oncol. Pharmacol. Desensitization Protocol to Carboplatin: A Technical Report. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Patients who previously received platinum compounds were excluded. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23, Published in 2017 Ann Oncol (2017) 28 (suppl 4): iv100iv118.Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan.